|
|||||||||||||||
|
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016 Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI) |
||||||||||||||
Issue: May 2024
Volume 9 | Issue 5
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.76
Issue per Year : 12
Volume Published : 9
Issue Published : 96
Article Submitted :
Article Published :
Total Authors :
Total Reviewer :
Total Countries :
Indexing Partner
Join RMS/Earn 300
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | CEFTRIXONE SERIOUS INFECTION DISEASE IN SEPTICEMIA |
| Authors Name: | Sakshi Kadam , Khopade Abhijit , Udamale Nikhil |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJNRD_207080
|
| Published Paper Id: | IJNRD2310272 |
| Published In: | Volume 8 Issue 10, October-2023 |
| DOI: | |
| Abstract: | Abstract Ceftriaxone belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. It is generally recognized as safe and effective when used as a single drug in the therapy of septicemia and other serious infections involving bacteremia in both adults and children. An advantage of ceftriaxone over other third-generation cephalosporins is its long serum half-life, which allows the drug to be given every 12 hours in children or less frequently in adults also Two potent third generation cephalosporins with similar antibacterial spectra, but different pharmacokinetics were compared in patients suffering from septicemia due to different organisms Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection, associated with a mortality rate over 25%, that has been designated a global health priority. Most of the sepsis is community-acquired, and progression can be insidious, making diagnosis difficult. Prognosis depends on early administration of broad-spectrum antibiotics and effective source control. Certain factors which are major determinants in the survival of the septic patient - age, underlying disease, infecting organism - are beyond the physician's control. Others, however, we can have some impact on. These include initial vigorous supportive treatment, early and appropriate antibiotic administration and timely surgical intervention. In the following discussion current understanding of the pathophysiology of sepsis is outlined, together with a practical approach to the problem of patient management. Risk factors for the development of septicemia, which are similar to those associated with any urinary tract infection, are reviewed. The "ABCs of Management" are outlined. Early recognition and effective management including selection of an effective antimicrobial agent for empiric therapy can have a direct impact on the patient's survival. Potential infecting type of bacteria are reviewed, and specific empiric therapies are described. In addition to antibiotic administration, rapid resuscitation and surgical drainage or debridement of the source of infection are integral parts of immediate treatment for sepsis. The importance of locating and draining (or removing) the source of infection is emphasized. Since sepsis is a systemic infection, patients must be monitored closely for failure of vital physiologic functions. Suggestions are offered for dealing with lack of response to antibiotic and supportive measures. Rapid diagnosis and effective management can improve the prognosis for septic patients. Ceftriaxone sodium MW: 552.600 g/mol MF: C18H16N8O7S3-2 IUPAC name: (7R)-7-[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoace. |
| Keywords: | : Ceftriaxone; Dose; Pharmacokinetics; Sepsis SEPSIS EPIDOMILOGY; INFECTION SITE; PATHOGEN; |
| Cite Article: | "CEFTRIXONE SERIOUS INFECTION DISEASE IN SEPTICEMIA", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.8, Issue 10, page no.c651-c657, October-2023, Available :http://www.ijnrd.org/papers/IJNRD2310272.pdf |
| Downloads: | 000118752 |
| ISSN: |
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID:IJNRD2310272 Registration ID: 207080 Published In: Volume 8 Issue 10, October-2023 DOI (Digital Object Identifier): Page No: c651-c657 Country: SOLAPUR, MAHARASHTRA, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijnrd.org/viewpaperforall?paper=IJNRD2310272 Published Paper PDF: https://www.ijnrd.org/papers/IJNRD2310272 |
| Share Article: |
|
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijnrd.org
| Semantic Scholar | Microsaoft Academic | ORCID | Zenodo |
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | PUBLON |
| DRJI | SSRN | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-4184
Impact Factor: 8.76 and ISSN APPROVED
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Social Media
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Join RMS/Earn 300
| Copyright © 2024 - All Rights Reserved - IJNRD |
Facebook Twitter Instagram LinkedIn